Home > Publications Database > Alzheimer's Disease and Small Vessel Disease Differentially Affect White Matter Microstructure. > print

001     270323
005     20240809090118.0
024 7 _ |a pmc:PMC11187968
|2 pmc
024 7 _ |a 10.1002/acn3.52071
|2 doi
024 7 _ |a pmid:38757392
|2 pmid
024 7 _ |a altmetric:163585031
|2 altmetric
037 _ _ |a DZNE-2024-00785
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Tranfa, Mario
|0 0000-0002-4451-4746
|b 0
245 _ _ |a Alzheimer's Disease and Small Vessel Disease Differentially Affect White Matter Microstructure.
260 _ _ |a Chichester [u.a.]
|c 2024
|b Wiley
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1721285594_15953
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Alzheimer's disease (AD) and cerebral small vessel disease (cSVD), the two most common causes of dementia, are characterized by white matter (WM) alterations diverging from the physiological changes occurring in healthy aging. Diffusion tensor imaging (DTI) is a valuable tool to quantify WM integrity non-invasively and identify the determinants of such alterations. Here, we investigated main effects and interactions of AD pathology, APOE-ε4, cSVD, and cardiovascular risk on spatial patterns of WM alterations in non-demented older adults.Within the prospective European Prevention of Alzheimer's Dementia study, we selected 606 participants (64.9 ± 7.2 years, 376 females) with baseline cerebrospinal fluid samples of amyloid β1-42 and p-Tau181 and MRI scans, including DTI scans. Longitudinal scans (mean follow-up time = 1.3 ± 0.5 years) were obtained in a subset (n = 223). WM integrity was assessed by extracting fractional anisotropy and mean diffusivity in relevant tracts. To identify the determinants of WM disruption, we performed a multimodel inference to identify the best linear mixed-effects model for each tract.AD pathology, APOE-ε4, cSVD burden, and cardiovascular risk were all associated with WM integrity within several tracts. While limbic tracts were mainly impacted by AD pathology and APOE-ε4, commissural, associative, and projection tract integrity was more related to cSVD burden and cardiovascular risk. AD pathology and cSVD did not show any significant interaction effect.Our results suggest that AD pathology and cSVD exert independent and spatially different effects on WM microstructure, supporting the role of DTI in disease monitoring and suggesting independent targets for preventive medicine approaches.
536 _ _ |a 353 - Clinical and Health Care Research (POF4-353)
|0 G:(DE-HGF)POF4-353
|c POF4-353
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |a Amyloid beta-Peptides
|2 NLM Chemicals
650 _ 7 |a Apolipoprotein E4
|2 NLM Chemicals
650 _ 7 |a tau Proteins
|2 NLM Chemicals
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Alzheimer Disease: pathology
|2 MeSH
650 _ 2 |a Alzheimer Disease: diagnostic imaging
|2 MeSH
650 _ 2 |a Female
|2 MeSH
650 _ 2 |a Cerebral Small Vessel Diseases: diagnostic imaging
|2 MeSH
650 _ 2 |a Cerebral Small Vessel Diseases: pathology
|2 MeSH
650 _ 2 |a Male
|2 MeSH
650 _ 2 |a White Matter: diagnostic imaging
|2 MeSH
650 _ 2 |a White Matter: pathology
|2 MeSH
650 _ 2 |a Aged
|2 MeSH
650 _ 2 |a Diffusion Tensor Imaging
|2 MeSH
650 _ 2 |a Middle Aged
|2 MeSH
650 _ 2 |a Amyloid beta-Peptides: cerebrospinal fluid
|2 MeSH
650 _ 2 |a Amyloid beta-Peptides: metabolism
|2 MeSH
650 _ 2 |a Apolipoprotein E4: genetics
|2 MeSH
650 _ 2 |a tau Proteins: cerebrospinal fluid
|2 MeSH
650 _ 2 |a tau Proteins: metabolism
|2 MeSH
650 _ 2 |a Prospective Studies
|2 MeSH
700 1 _ |a Lorenzini, Luigi
|b 1
700 1 _ |a Collij, Lyduine E
|b 2
700 1 _ |a Vállez García, David
|b 3
700 1 _ |a Ingala, Silvia
|b 4
700 1 _ |a Pontillo, Giuseppe
|b 5
700 1 _ |a Pieperhoff, Leonard
|b 6
700 1 _ |a Maranzano, Alessio
|0 0000-0002-3642-9584
|b 7
700 1 _ |a Wolz, Robin
|b 8
700 1 _ |a Haller, Sven
|b 9
700 1 _ |a Blennow, Kaj
|b 10
700 1 _ |a Frisoni, Giovanni
|b 11
700 1 _ |a Sudre, Carole H
|b 12
700 1 _ |a Chételat, Gael
|0 0000-0002-4889-7932
|b 13
700 1 _ |a Ewers, Michael
|0 P:(DE-2719)9000543
|b 14
700 1 _ |a Payoux, Pierre
|b 15
700 1 _ |a Waldman, Adam
|b 16
700 1 _ |a Martinez-Lage, Pablo
|0 0000-0001-5404-9967
|b 17
700 1 _ |a Schwarz, Adam J
|b 18
700 1 _ |a Ritchie, Craig W
|b 19
700 1 _ |a Wardlaw, Joanna M
|0 0000-0002-9812-6642
|b 20
700 1 _ |a Gispert, Juan Domingo
|b 21
700 1 _ |a Brunetti, Arturo
|b 22
700 1 _ |a Mutsaerts, Henk J M M
|0 0000-0003-0894-0307
|b 23
700 1 _ |a Wink, Alle Meije
|b 24
700 1 _ |a Barkhof, Frederik
|b 25
773 _ _ |a 10.1002/acn3.52071
|g Vol. 11, no. 6, p. 1541 - 1556
|0 PERI:(DE-600)2740696-9
|n 6
|p 1541 - 1556
|t Annals of Clinical and Translational Neurology
|v 11
|y 2024
|x 2328-9503
856 4 _ |u https://pub.dzne.de/record/270323/files/DZNE-2024-00785%20SUP.docx
856 4 _ |y OpenAccess
|u https://pub.dzne.de/record/270323/files/DZNE-2024-00785.pdf
856 4 _ |u https://pub.dzne.de/record/270323/files/DZNE-2024-00785%20SUP.doc
856 4 _ |u https://pub.dzne.de/record/270323/files/DZNE-2024-00785%20SUP.odt
856 4 _ |u https://pub.dzne.de/record/270323/files/DZNE-2024-00785%20SUP.pdf
856 4 _ |y OpenAccess
|x pdfa
|u https://pub.dzne.de/record/270323/files/DZNE-2024-00785.pdf?subformat=pdfa
909 C O |o oai:pub.dzne.de:270323
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 14
|6 P:(DE-2719)9000543
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-353
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 0
914 1 _ |y 2024
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2023-08-22
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2023-08-22
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2023-08-22
915 _ _ |a Creative Commons Attribution-NonCommercial-NoDerivs CC BY-NC-ND 4.0
|0 LIC:(DE-HGF)CCBYNCND4
|2 HGFVOC
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b ANN CLIN TRANSL NEUR : 2022
|d 2023-08-22
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2021-04-16T15:13:11Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2021-04-16T15:13:11Z
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2023-08-22
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2023-08-22
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2023-08-22
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2023-08-22
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2023-08-22
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b ANN CLIN TRANSL NEUR : 2022
|d 2023-08-22
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2023-08-22
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0320
|2 StatID
|b PubMed Central
|d 2023-08-22
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2023-08-22
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b DOAJ : Anonymous peer review
|d 2021-04-16T15:13:11Z
920 1 _ |0 I:(DE-2719)1111015
|k Clinical Research (Munich)
|l Clinical Research (Munich)
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-2719)1111015
980 1 _ |a FullTexts

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21